Nivolumab (anti-PD-1)
Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.
| Supplier | Selleck Chemicals |
|---|---|
| Product # | A2002 |
| Sku # | A2002-1mg*5 |
| Pricing | 1mg*5, $707.00 |
Citations for this product:
-
bioRxiv - Cancer Biology 2022Quote: ... Nivolumab (anti-PD-1, cat#A2002 from Selleck Chemicals) or Durvalumab (anti-PD-L1 ...